GlassScriptPhysician profile
Mehmood Mehdi
NPI 1922017987
$1,391.44
in general payments reported to CMS, 2019-2025
21 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $90.23 · 2022: $90.24 · 2023: $123 · 2024: $512 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.59 |
| Education | $220.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $388.39 | 2019-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $165.72 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $145.65 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $102.59 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $100.29 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $83.68 | 2019-2025 | Trintellix |
| Tris Pharma INC | $62.36 | 2024-2025 | Dyanavel Xr |
| Lundbeck LLC | $55.07 | 2020-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $42.01 | 2019 | |
| Bausch Health US, LLC | $39.93 | 2024-2025 | Wellbutrin, Aplenzin |
| Indivior INC. | $28.89 | 2022 | |
| Ironshore Pharmaceuticals INC. | $28.29 | 2019-2024 | |
| Corium, LLC | $20.38 | 2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $19.24 | 2024 | Fanapt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $17.46 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $16.60 | 2024 | Quviviq |
| Shire North American Group INC | $16.38 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.09 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.08 | 2022 | |
| Allergan, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehmood Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.